| Abstract |
Histamine interacts with histamine H4 receptor (HRH4) to impact antipsychotic response. Pharmacogenetic information about this receptor could therefore be useful in developing individualized therapy. The aim of this investigation was to clarify whether polymorphisms at humanHRH4gene alter risperidone efficacy. We genotyped 5 tag-single nucleotide polymorphisms of theHRH4gene and analyzed their association with the reduction in Positive and Negative Syndrome Scale (PANSS) scores in a group of 113 Chinese Han patients with精神分裂症who were following an 8-week period of risperidone monotherapy. Using ?(2), analysis of variance, haplotype, and receiver operating characteristics analysis, we found thatHRH4common variant rs4483927 is significantly associated with risperidone efficacy and that its TT genotype predicts poor therapeutic response both on the positive, negative, and general subscales and on the total scale of PANSS scores (P = 0.017, 0.019, 0.021, and 0.002, respectively, in analysis of variance). Our results provide the first evidence that anHRH4polymorphism may be a molecular marker for the prediction of risperidone efficacy and suggest novel pharmacologic links betweenHRH4gene and treatment of精神分裂症. |